Abbott Laboratories Stock Pre-Market (-5.2%) : 2026 Guidance Misses Analyst Expectations

January 22nd, 2026 by Trefis Team
+32.48%
Upside
109
Market
144
Trefis
ABT: Abbott Laboratories logo
ABT
Abbott Laboratories

ABT shares are under significant pressure, dropping -5.2% pre-market after releasing Q4 2025 results. The trigger appears to be forward guidance for 2026 that fell short of Wall Street consensus. The sentiment has soured on a headline beat. Will this be a buy-the-dip opportunity or the start of a larger correction?

This is a sentiment-driven move, not a structural break. While Q4 EPS of $1.50 was a beat, the company’s full-year 2026 adjusted EPS guidance of $5.55-$5.80 has a midpoint that is below the consensus estimate of $5.73.

  • The projected 10% EPS growth at the midpoint is still healthy but represents a deceleration from prior periods.
  • Organic sales growth guidance of 6.5%-7.5% is solid, suggesting the core business remains intact.
  • The long-term thesis, driven by Medical Devices like FreeStyle Libre and new cardiology products, is unchanged.
But here is the interesting part. You are reading about this -5.2% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to reduce exposure to losers.

Relevant Articles
  1. Pay Less, Gain More: RMD Tops Abbott Laboratories Stock
  2. Why RMD Could Outperform Abbott Laboratories Stock
  3. Better Value & Growth: RMD, BDX Lead Abbott Laboratories Stock
  4. RMD, BDX Top Abbott Laboratories Stock on Price & Potential
  5. Better Value & Growth: RMD, BDX Lead Abbott Laboratories Stock
  6. Pay Less, Grow More: RMD, BDX Outshine Abbott Laboratories Stock

Playbook On Market Open

The session will be a battle between the headline guidance disappointment and the underlying fundamental strength. Watch the earnings call commentary for confirmation of the bull or bear case.

  • Key resistance at $117 for bullish reversal towards gap fill.
  • Support at pre-market lows around $114.50 confirms bearish sentiment.
  • Watch $115.00 as a critical pivot for intraday direction.

Verdict

BUY THE OPEN if $115.00 holds in the first 30 minutes, aiming for gap fill. Conversely, FADE THE GAP if $115.00 breaks decisively, targeting further downside.
Understanding price behavior can give you an edge. See more.

Want to make sure you never miss the explainer on ABT’s next move? Stay updated with Upcoming Events and Latest Analyses

That’s for now, but so much more goes into evaluating a stock from long-term investment perspective. We make it easy with our Investment Highlights

A Multi Asset Portfolio Gives You Safer Smarter Growth

Markets move differently but a mix of assets smooths volatility. A multi asset portfolio keeps you invested and reduces the impact of sharp drops in any single area.

The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices